Olmesartan
Based on 12 publication(s) in Google Scholar
Olmesartan (RNH-6270) is an angiotensin II receptor (AT1R) antagonist used to treat high blood pressure.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.91%
- CAS No.: 144689-24-7
- Formule: C24H26N6O3
- Masse moléculaire:446.50
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
GPCR/G Protein Compound Library
HY-L006
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Drug Repurposing Compound Library
HY-L035
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
Neurotransmitter Receptor Compound Library
HY-L062
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Angiogenesis-Related Compound Library
HY-L088
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Off-patent Drug Library
HY-L141
-
Antihypertensive Compound Library
HY-L145
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Nephrotoxicity Compound Library
HY-L229
-
RNA Binding Bioactive Compound Library
HY-L248
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) Olmesartan
More- Int J Biol Macromol. 2025 Mar 25:142184. [Abstract]
- Sleep. 2018 Mar 1;41(3). [Abstract]
- Am J Physiol Cell Physiol. 2022 Jan 1;322(1):C73-C85. [Abstract]
- Cell Signal. 2024 Aug 20:111355. [Abstract]
- Pharm Res. 2024 May;41(5):849-861. [Abstract]
- J Lumin. 2018 Nov; 203;616-628.
- Int J Biochem Cell Biol. 2020 Apr;121:105703. [Abstract]
- J Physiol Sci. 2018 Mar;68(2):153-164. [Abstract]
- Biomed Res Int. 2022 Aug 26:2022:4710993. [Abstract]
- Toxicol Mech Methods. 2015;25(8):614-21. [Abstract]
- J Chemother. 2016 Aug;28(4):314-20. [Abstract]
- Biomed Pharmacother. 2017 Sep:93:429-434. [Abstract]
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Histological Imaging/Staining
-
WB
-
Others
-
Others
Voir tous les produits spécifiques à Isoform Angiotensin Receptor
More
Activité biologique
|
AT1 Receptor |
Olmesartan (0.7-5 mM; 24, 48 and 72 h) inhibits the growth of HeLa cells as a concentration- and time-dependent mode[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human cervical cancer cell line (HeLa)
-
Concentration:0.7- 5 mM
-
Incubation Time:24, 48 and 72 h
-
Result:IC50s against HeLa cell line are 4.685 and 1.651 mM for 48 and 72 h, respectively.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 144689-24-7
-
Appearance Solid
-
Masse moléculaire 446.50
-
Formule C24H26N6O3
-
Color White to off-white
-
SMILES
O=C(O)C1=C(N=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NN=NN4)CCC)C(O)(C)C
-
Synonyms
RNH-6270
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (12)
-
Journal Impact Factor
-
Most Recent
-
Int J Biol Macromol
Natural angiotensin II type 1 receptor inhibitors: Virtual screening and in vitro evaluation of beta-1,2,3,4,6-penta-O-galloyl-d-glucopyranose, icarrin, and sesamin for osteoarthritis therapy. [Abstract]2025 Mar 25:142184. PMID: 40147655
Olmesartan purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2025 Mar 25:142184. [Abstract]
Effect of Olmesartan treatment on cell viability of ATDC5 cell line after 14 days of differentiation and stimulation with IL-1β.
-
Sleep
Sleep/Wake Behaviors in Mice During Pregnancy and Pregnancy-Associated Hypertensive Mice. [Abstract]2018 Mar 1;41(3). PMID: 29309677 -
Am J Physiol Cell Physiol
Glucose consumption of vascular cell types in culture: toward optimization of experimental conditions. [Abstract]2022 Jan 1;322(1):C73-C85. PMID: 34817269
Olmesartan purchased from MedChemExpress. Usage Cited in: Am J Physiol Cell Physiol. 2022 Jan 1;322(1):C73-C85. [Abstract]
Role of AT1 receptor and glycolysis in glucose consumption in AFs with AngII stimulation. Conditioned media glucose concentrations were monitored at 48-h time points with AngII (AII) or vehicle (veh: 0.1% H2O final) treatment in purchased AFs pretreated with vehicle (veh: 0.1% DMSO final), 1 mM 2DG, or 10 μM Olmesartan (ARB) in MG-DMEM.
-
Cell Signal
Angiotensin II depends on hippo/YAP signaling to reprogram angiogenesis and promote liver fibrosis. [Abstract]2024 Aug 20:111355. PMID: 39173854
Olmesartan purchased from MedChemExpress. Usage Cited in: Cell Signal. 2024 Aug 20:111355. [Abstract]
Olmesartan reduces liver fibrosis in CCl4-induced chronic liver injury models. Histological analyses were performed on mouse liver sections using H&E and Sirius red staining, and immunofluorescence labeling against α-SMA.
Olmesartan purchased from MedChemExpress. Usage Cited in: Cell Signal. 2024 Aug 20:111355. [Abstract]
Western blot analysis of YAP and TAZ expression after Olmesartan treatment.
-
Pharm Res
Conversion of Olmesartan to Olmesartan Medoxomil, A Prodrug that Improves Intestinal Absorption, Confers Substrate Recognition by OATP2B1. [Abstract]2024 May;41(5):849-861. PMID: 38485855 -
-
Int J Biochem Cell Biol
Angiotensin II inhibits osteogenic differentiation of isolated synoviocytes by increasing DKK-1 expression. [Abstract]2020 Apr;121:105703. PMID: 32014499 -
J Physiol Sci
TRPC3 participates in angiotensin II type 1 receptor-dependent stress-induced slow increase in intracellular Ca2+ concentration in mouse cardiomyocytes. [Abstract]2018 Mar;68(2):153-164. PMID: 28105583
Olmesartan purchased from MedChemExpress. Usage Cited in: J Physiol Sci. 2018 Mar;68(2):153-164. [Abstract]
The significant slow increase in [Ca2+] transient at 300 s after the stretch (SSC) was suppressed by the inhibitors Olmesartan (10 μM).
-
Biomed Res Int
Olmesartan Improves Hepatic Sinusoidal Remodeling in Mice with Carbon Tetrachloride-Induced Liver Fibrosis. [Abstract]2022 Aug 26:2022:4710993. PMID: 36060127 -
Toxicol Mech Methods
Synergistic, cytotoxic and apoptotic activities of olmesartan with NF-κB inhibitor against HeLa human cell line. [Abstract]2015;25(8):614-21. PMID: 26330000 -
J Chemother
Angiotensin II receptor antagonist olmesartan and NF-kappaB inhibitor as cytotoxic and apoptotic agents in MCF-7 human cell line. [Abstract]2016 Aug;28(4):314-20. PMID: 26138656 -
Biomed Pharmacother
The role of ROS and NF-κB pathway in olmesartan induced-toxicity in HeLa and mcf-7 cell lines. [Abstract]2017 Sep:93:429-434. PMID: 28666209
Olmesartan purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2017 Sep:93:429-434. [Abstract]
Effect of Olmesartan and Bay11-7082 on the level of apoptotic proteins.The HeLa (4A) and Mcf-7 (4B) are treated with 5 mM Olmesartan and 25 μM of Bay11-7082 for 24 h. Western blot analysis is performed to determine the level of Bax,caspase-3, and IκB.
Solvant et solubilité
DMSO : 20.83 mg/mL (46.65 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.60 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.60 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Yanagihara H, et al. Effects of telmisartan and olmesartan on insulin sensitivity and renal function in spontaneously hypertensive rats fed a high fat diet. J Pharmacol Sci. 2016 Jul;131(3):190-7. [Content Brief]
[2]. Tanno T, et al. Olmesartan Inhibits Cardiac Hypertrophy in Mice Overexpressing Renin Independently of Blood Pressure: Its Beneficial Effects on ACE2/Ang(1-7)/Mas Axis and NADPH Oxidase Expression. J Cardiovasc Pharmacol. 2016 Jun;67(6):503-9. [Content Brief]
[3]. Bakhtiari E, et al. Synergistic, cytotoxic and apoptotic activities of olmesartan with NF-κB inhibitor against HeLa human cell line. Toxicol Mech Methods. 2015;25(8):614-21. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2396 mL | 11.1982 mL | 22.3964 mL | 55.9910 mL |
| 5 mM | 0.4479 mL | 2.2396 mL | 4.4793 mL | 11.1982 mL | |
| 10 mM | 0.2240 mL | 1.1198 mL | 2.2396 mL | 5.5991 mL | |
| 15 mM | 0.1493 mL | 0.7465 mL | 1.4931 mL | 3.7327 mL | |
| 20 mM | 0.1120 mL | 0.5599 mL | 1.1198 mL | 2.7996 mL | |
| 25 mM | 0.0896 mL | 0.4479 mL | 0.8959 mL | 2.2396 mL | |
| 30 mM | 0.0747 mL | 0.3733 mL | 0.7465 mL | 1.8664 mL | |
| 40 mM | 0.0560 mL | 0.2800 mL | 0.5599 mL | 1.3998 mL |
Olmesartan Related Classifications
HY-17004 Related Classifications
Powered by Bioz